The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.

Coleman, R J; Lange, K W; Quinn, N P; Loper, A E; Bondi, J V; Hichens, M; Stahl, S M; Marsden, C D

Coleman, R J; Lange, K W; Quinn, N P; Loper, A E; Bondi, J V; Hichens, M; Stahl, S M; Marsden, C D.

Affiliation

Coleman RJ; Institute of Neurology, London, U.K.

Mov Disord ; 4(2): 129-38, 1989.

Article in En | MEDLINE | ID: mdl-2733705

Subject(s)

Antiparkinson Agents/antagonists & inhibitors; Dopamine Antagonists; Oxazines/administration & dosage; Parkinson Disease/drug therapy; Administration, Cutaneous; Adult; Antiparkinson Agents/pharmacokinetics; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa/administration & dosage; Middle Aged; Motor Skills/drug effects; Oxazines/pharmacokinetics; Parkinson Disease/blood

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Oxazines / Parkinson Disease / Dopamine Antagonists / Antiparkinson Agents Limits: Adult / Humans / Middle aged Language: En Journal: Mov Disord Journal subject: NEUROLOGIA Year: 1989 Type: Article Affiliation country: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links